京中院就金通灵证券虚假陈述特别代表人诉讼案件依法作出一审先行判决 证监会回应

Core Viewpoint - The China Securities Regulatory Commission (CSRC) views the recent ruling in the Jintongling Securities false statement representative lawsuit as a significant development in the enforcement of securities law, following similar cases involving Kangmei Pharmaceutical and Zeda Yisheng [1] Group 1: Legal Implications - The Jintongling case represents the third instance of a substantive judgment under the special representative lawsuit procedure for securities false statement liability disputes [1] - The case effectively demonstrates the function of the special representative lawsuit system in allowing collective low-cost protection of investor rights and resolving disputes [1] Group 2: Regulatory Perspective - The CSRC emphasizes that the special representative lawsuit system serves as an important legal mechanism for the coordinated governance of securities market regulation and judicial adjudication [1] - This ruling is expected to deter potential violations in the securities market by reinforcing the legal consequences of false statements [1]